124 related articles for article (PubMed ID: 9033651)
1. Pleiotropic over-expression of multidrug-resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model.
Cappellen D; Bénard J
Int J Cancer; 1997 Feb; 70(4):430-6. PubMed ID: 9033651
[TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
[TBL] [Abstract][Full Text] [Related]
3. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
4. The mycN/max protein complex in neuroblastoma. Short review.
Wenzel A; Schwab M
Eur J Cancer; 1995; 31A(4):516-9. PubMed ID: 7576956
[TBL] [Abstract][Full Text] [Related]
5. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
6. A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteins.
Billaud M; Isselbacher KJ; Bernards R
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2739-43. PubMed ID: 8464883
[TBL] [Abstract][Full Text] [Related]
7. Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse.
Ferrandis E; Da Silva J; Riou G; Bénard I
Cancer Res; 1994 Apr; 54(8):2256-61. PubMed ID: 8174136
[TBL] [Abstract][Full Text] [Related]
8. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells.
Wenzel A; Cziepluch C; Hamann U; Schürmann J; Schwab M
EMBO J; 1991 Dec; 10(12):3703-12. PubMed ID: 1935896
[TBL] [Abstract][Full Text] [Related]
9. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
Spengler BA; Lazarova DL; Ross RA; Biedler JL
Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
11. Myc meets its Max.
Cole MD
Cell; 1991 May; 65(5):715-6. PubMed ID: 2040011
[No Abstract] [Full Text] [Related]
12. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions.
Peverali FA; Orioli D; Tonon L; Ciana P; Bunone G; Negri M; Della-Valle G
Oncogene; 1996 Jan; 12(2):457-62. PubMed ID: 8570225
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
16. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
17. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
18. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites.
Zervos AS; Gyuris J; Brent R
Cell; 1993 Jan; 72(2):223-32. PubMed ID: 8425219
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.
Lacave R; Coulet F; Ricci S; Touboul E; Flahault A; Rateau JG; Cesari D; Lefranc JP; Bernaudin JF
Br J Cancer; 1998 Mar; 77(5):694-702. PubMed ID: 9514046
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
